$377 Million is the total value of Opaleye Management Inc.'s 44 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 57.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TARA | New | ARTARA THERAPEUTICS INC | $52,142,000 | – | 2,208,472 | +100.0% | 13.82% | – |
| FTSV | Sell | FORTY SEVEN INC | $36,784,000 | +66.2% | 385,500 | -31.4% | 9.75% | +124.6% |
| OCUL | Buy | OCULAR THERAPEUTIX INC | $25,356,000 | +25.7% | 5,122,500 | +0.3% | 6.72% | +69.7% |
| Sell | APTOSE BIOSCIENCES INC | $23,891,000 | +3.1% | 4,022,000 | -1.5% | 6.33% | +39.3% | |
| NLTX | Buy | NEOLEUKIN THERAPEUTICS INC | $15,932,000 | -6.4% | 1,400,000 | +1.4% | 4.22% | +26.4% |
| CDXS | CODEXIS INC | $15,624,000 | -29.9% | 1,400,000 | 0.0% | 4.14% | -5.3% | |
| EIDX | EIDOS THERAPEUTICS INC | $15,459,000 | -14.6% | 315,550 | 0.0% | 4.10% | +15.3% | |
| ETON | Buy | ETON PHARMACEUTICALS INC | $14,924,000 | +41.1% | 3,640,000 | +147.7% | 3.96% | +90.5% |
| CCXI | CHEMOCENTRYX INC | $14,529,000 | +4.9% | 361,600 | 0.0% | 3.85% | +41.7% | |
| STXS | Sell | STEREOTAXIS INC | $11,662,000 | -47.1% | 3,861,500 | -6.1% | 3.09% | -28.5% |
| QURE | UNIQURE NV | $9,965,000 | -33.8% | 210,000 | 0.0% | 2.64% | -10.6% | |
| ODT | Buy | ODONATE THERAPEUTICS INC | $9,940,000 | -13.7% | 360,000 | +1.4% | 2.63% | +16.5% |
| IMMY | Buy | HARROW HEALTH | $9,550,000 | -47.5% | 2,500,000 | +6.8% | 2.53% | -29.1% |
| ATXI | AVENUE THERAPEUTICS INC | $9,253,000 | -6.9% | 1,035,000 | 0.0% | 2.45% | +25.7% | |
| DCPH | Sell | DECIPHERA PHARMACEUTICALS IN | $9,140,000 | -34.6% | 222,000 | -1.1% | 2.42% | -11.7% |
| XOMA | Buy | XOMA CORP DEL | $7,875,000 | -22.8% | 387,000 | +3.6% | 2.09% | +4.4% |
| Buy | FORTRESS BIOTECH INC | $7,239,000 | -26.4% | 3,830,000 | +0.1% | 1.92% | -0.6% | |
| KALA | New | KALA PHARMACEUTICALS INC | $7,234,000 | – | 782,000 | +100.0% | 1.92% | – |
| MTEM | New | MOLECULAR TEMPLATES INC | $7,089,000 | – | 533,400 | +100.0% | 1.88% | – |
| CERC | Buy | CERECOR INC | $5,464,000 | -53.7% | 2,203,100 | +0.6% | 1.45% | -37.5% |
| CRNX | Buy | CRINETICS PHARMACEUTICALS INC | $5,421,000 | -18.8% | 368,750 | +38.6% | 1.44% | +9.7% |
| FGEN | FIBROGEN INC | $5,074,000 | -19.0% | 146,000 | 0.0% | 1.34% | +9.4% | |
| EDAP | Buy | EDAP TMS SAsponsored adr | $4,979,000 | -37.0% | 2,193,500 | +22.9% | 1.32% | -15.0% |
| MYOV | New | MYOVANT SCIENCES LTD | $4,953,000 | – | 656,000 | +100.0% | 1.31% | – |
| TGTX | Sell | TG THERAPEUTICS INC | $4,851,000 | -24.6% | 493,000 | -14.9% | 1.28% | +1.8% |
| KDMN | Buy | KADMON HOLDINGS INC | $4,828,000 | +13.3% | 1,152,250 | +22.5% | 1.28% | +53.0% |
| ZYME | Sell | ZYMEWORKS INC | $4,718,000 | -40.7% | 133,000 | -24.0% | 1.25% | -19.9% |
| TCDA | TRICIDA INC | $4,268,000 | -41.6% | 194,000 | 0.0% | 1.13% | -21.1% | |
| CPRX | New | CATALYST PHARMACEUTICALS INC | $4,043,000 | – | 1,050,000 | +100.0% | 1.07% | – |
| VSTM | New | VERASTEM INC | $3,865,000 | – | 1,463,900 | +100.0% | 1.02% | – |
| MGTA | Sell | MAGENTA THERAPEUTICS INC | $2,730,000 | -59.4% | 434,712 | -3.4% | 0.72% | -45.2% |
| NERV | New | MINERVA NEUROSCIENCES INC | $2,710,000 | – | 450,100 | +100.0% | 0.72% | – |
| MGNX | Buy | MACROGENICS INC | $2,458,000 | +12.7% | 422,300 | +110.6% | 0.65% | +52.1% |
| CDTX | New | CIDARA THERAPEUTICS INC | $2,247,000 | – | 906,056 | +100.0% | 0.60% | – |
| FLXN | Sell | FLEXION THERAPEUTICS INC | $2,216,000 | -74.2% | 281,600 | -32.2% | 0.59% | -65.2% |
| RDUS | Sell | RADIUS HEALTH INC | $2,171,000 | -35.9% | 167,000 | -0.6% | 0.58% | -13.5% |
| AMRN | Sell | AMARIN CORP PLCsponsored adr | $1,820,000 | -87.2% | 455,000 | -31.6% | 0.48% | -82.8% |
| KALV | New | KALVISTA PHARMACEUTICALS INC | $1,721,000 | – | 225,000 | +100.0% | 0.46% | – |
| PRVB | New | PROVENTION BIO INC | $1,527,000 | – | 166,000 | +100.0% | 0.40% | – |
| SELB | New | SELECTA BIOSCIENCES INC | $940,000 | – | 390,000 | +100.0% | 0.25% | – |
| TELA | Sell | TELA BIO INC | $633,000 | -72.1% | 81,000 | -53.7% | 0.17% | -62.2% |
| ACAD | Sell | ACADIA PHARMACEUTICALS INC | $63,000 | -99.3% | 1,500 | -99.3% | 0.02% | -99.0% |
| New | OCULAR THERAPEUTIX INCcall | $53,000 | – | 1,000 | +100.0% | 0.01% | – | |
| BLRX | BIOLINERX LTDsponsored adr | $22,000 | -42.1% | 16,667 | 0.0% | 0.01% | -14.3% | |
| FENC | Exit | FENNEC PHARMACEUTICALS INC | $0 | – | -12,000 | -100.0% | -0.02% | – |
| PRTO | Exit | PROTEON THERAPEUTICS INC | $0 | – | -188,144 | -100.0% | -0.02% | – |
| RYTM | Exit | RHYTHM PHARMACEUTICALS INC | $0 | – | -110,500 | -100.0% | -0.50% | – |
| QTRX | Exit | QUANTERIX CORP | $0 | – | -132,200 | -100.0% | -0.61% | – |
| AQST | Exit | AQUESTIVE THERAPEUTICS INC | $0 | – | -738,500 | -100.0% | -0.84% | – |
| ACHN | Exit | ACHILLION PHARMACEUTICALS INC | $0 | – | -760,000 | -100.0% | -0.90% | – |
| RARX | Exit | RA PHARMACEUTICALS INC | $0 | – | -141,800 | -100.0% | -1.31% | – |
| BPMC | Exit | BLUEPRINT MEDICINES CORP | $0 | – | -100,000 | -100.0% | -1.57% | – |
| BHVN | Exit | BIOHAVEN PHARMACEUTICAL HLDG | $0 | – | -165,000 | -100.0% | -1.76% | – |
| PTCT | Exit | PTC THERAPEUTICS INC | $0 | – | -191,000 | -100.0% | -1.80% | – |
| AXGN | Exit | AXOGEN INC | $0 | – | -700,000 | -100.0% | -2.46% | – |
| ITCI | Exit | INTRA CELLULAR THERAPIES INC | $0 | – | -406,600 | -100.0% | -2.74% | – |
| BOLD | Exit | AUDENTES THERAPEUTICS INC | $0 | – | -292,000 | -100.0% | -3.43% | – |
| TPTX | Exit | TURNING POINT THERAPEUTICS INC | $0 | – | -340,500 | -100.0% | -4.16% | – |
| EPZM | Exit | EPIZYME INC | $0 | – | -1,384,200 | -100.0% | -6.68% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CODEXIS INC | 39 | Q3 2023 | 10.9% |
| CHIMERIX INC | 31 | Q3 2022 | 16.4% |
| XOMA CORP DEL | 27 | Q3 2023 | 3.6% |
| FIBROGEN INC | 26 | Q1 2021 | 6.8% |
| BIOLINERX LTD (Does not reflect a reverse stock split effectuated after June 30, 2019) | 26 | Q1 2020 | 2.4% |
| OCULAR THERAPEUTIX INC | 24 | Q3 2023 | 17.6% |
| AXOGEN INC | 20 | Q4 2019 | 18.7% |
| ETON PHARMACEUTICALS INC | 20 | Q3 2023 | 5.6% |
| AMARIN CORP PLC | 20 | Q4 2020 | 6.6% |
| IMPRIMIS PHARMACEUTICALS INC | 19 | Q1 2020 | 5.9% |
View Opaleye Management Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CHIMERIX INCSold out | February 13, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc. | January 23, 2023 | 1,560,000 | 3.6% |
| TELA Bio, Inc. | June 10, 2022 | 1,557,500 | 10.7% |
| Gemini Therapeutics, Inc. /DESold out | February 01, 2022 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | January 26, 2022 | 0 | 0.0% |
| AVENUE THERAPEUTICS, INC. | February 12, 2021 | 9 | 11.0% |
| Cardiff Oncology, Inc. | February 12, 2021 | 9 | 11.0% |
| EDAP TMS SA | February 12, 2021 | 9 | 11.0% |
| Fortress Biotech, Inc. | February 12, 2021 | 9 | 11.0% |
| Gemini Therapeutics, Inc. /DE | February 12, 2021 | 9 | 11.0% |
View Opaleye Management Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-25 |
| 4 | 2024-04-24 |
| 4 | 2024-04-19 |
| SC 13G/A | 2024-04-09 |
| SC 13G | 2024-04-08 |
| 4 | 2024-03-28 |
| 4 | 2024-03-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Opaleye Management Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.